West Pharmaceutical Servs Earnings & Forecasts

West Pharmaceutical Servs (WST) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

四半期利益の驚きの金額

会計四半期	報告日	実質EPS	推定EPS	驚き％
Q2	Jul 23, 2026	$2.37	$2.08	13.9 %
Q1	Apr 23, 2026	$2.13	$1.68	26.8 %
Q4	Feb 12, 2026	$2.04	$1.83	11.5 %
Q3	Oct 23, 2025	$1.96	$1.68	16.7 %

Quarterly Revenue (Billions)

四半期売上高の驚きの金額

会計四半期	報告日	実際の収益	推定収益	驚き％
Q2	Jul 23, 2026	$872.30M	$838.00M	4.09 %
Q1	Apr 23, 2026	$844.90M	$779.18M	8.44 %
Q4	Feb 12, 2026	$805.00M	$794.58M	1.31 %
Q3	Oct 23, 2025	$804.60M	$786.83M	2.26 %

West Pharmaceutical Servs Guidance

West Pharmaceutical Servs (WST) は、7 23, 2026 年に fiscal year 2026 のガイダンスを最後に発表しました。同社は 1 株当たり利益を $8.85 - $9.05 の範囲と予想し、コンセンサス EPS 予想は $8.61 でした。West Pharmaceutical Servs も、この期間の売上高を $3.35B - $3.38B の範囲と予想しました。

以前のガイダンスと比較すると、West Pharmaceutical ServsはEPS見通しを以前の範囲である引き上げから$8.4 - $8.75に引き上げました。売上高については、同社は売上高予測を以前の範囲である引き上げから$3.29B - $3.35Bに引き上げました。

West Pharmaceutical Servsは、18から10 27, 2022の間に7 23, 2026ガイダンスの更新を発表しました。During this period, the company raised its outlook 13 times and lowered it 3 times, providing investors with insight into management's evolving expectations.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$2.08	$1.68	$1.83	$1.68
Actual	$2.37	$2.13	$2.04	$1.96
Surprise	+13.9%	+26.8%	+11.5%	+16.7%
Revenue
Estimate	$838.0M	$779.2M	$794.6M	$786.8M
Actual	$872.3M	$844.9M	$805.0M	$804.6M
Surprise	+4.09%	+8.44%	+1.31%	+2.26%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$2.19	$2.27	$2.27	$2.53
Revenue
Consensus	$826.0M	$827.8M	—	—

More with Benzinga EdgeGet Access

Earnings & Guidance News

West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum

West Pharmaceutical reported Q2 earnings and revenue beat, higher 2026 guidance, and continued strength in GLP-1 and HVP products.

Vandana Singh

Earnings Scheduled For July 23, 2026

Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is expected to report

Benzinga Insights

PRO
West Pharmaceutical Servs Raises FY2026 Adj EPS Guidance from $8.40-$8.75 to $8.85-$9.05 vs $8.61 Est; Raises FY2026 Sales Guidance from $3.295B-$3.350B to $3.345B-$3.380B vs $3.332B Est

West Pharmaceutical Servs (NYSE:WST) raises FY2026 Adj EPS guidance from $8.40-$8.75 to $8.85-$9.05 vs $8.61 analyst estimate. Raises FY2026 sales outlook from $3.295 billion-$3.350 billion to $3.345 billion-$3.380

Benzinga Newsdesk

West Pharmaceutical Services Inc